Fortifying Food with Folic Acid

ABSTRACT

Folic acid supplementation may help prevent the following three common and important disorders: neural tube defect pregnancies, ischemic heart disease and strokes, and possibly colon cancer. Several studies have irrefutably established that folic acid supplementation in proper doses reduces neural tube defect pregnancies. Fortified food would be the most reliable way to address this health issue.

Several epidemiologic reports have established a close link between hyperhomocysteinemia and ischemic heart disease. This is supported by evidence obtained from genetic defects leading to elevated plasma levels of homocysteine. There is reasonable evidence to conclude that hyperhomocysteinemia is the actual cause of excessive cardiac diseases. Again, folic acid supplementation in proper doses could potentially reduce ischemic heart disease by 40%.

There is also some evidence to suggest that folic acid treatment reduces the incidence of colon cancer.

The reduction in all three health problems is dependent upon the dose of folic acid administered. The levels needed are rarely supplied by the daily food intake, even under ideal conditions, although breakfast cereals address this problem at least in part. It is proposed that flour be fortified because it is a food product heavily used by most people, and that governmental agencies should oversee such programs because they are responsible for setting public health policies.

KEYWORD

Homocysteine - hyperhomocysteinemia - folic acid - neural tube defect pregnancies - ischemic heart disease - colon cancer

REFERENCES

• 1 Wald N J, Bower C. Folic acid and the prevention of neural tube defects.  BMJ . 1995;  310 1019-1020
• 2 Malinow M R, Duell P B, Hess D L. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease.  N Engl J Med . 1998;  338 1009-1015
• 3 Jacques P F, Selhub J, Bostom A G, Wilson P WF, Rosenberg I H. The effect of folic acid fortification on plasma folate and total homocysteine concentrations.  N Engl J Med . 2099;  340 1449-1454
• 4 Cuskelly G J, McNulty H, Scott J M. Effect of increasing dietary folate on red-cell folate: Implications for prevention of neural tube defects.  Lancet . 1996;  347 657-659
• 5 MRC Vitamin Study Research Group. Prevention of neural tube defects: Results of the MRC vitamin study.  Lancet . 1991;  338 132-137
• 6 Botto L D, Moore C A, Khoury M J, Erickson J D. Neural-tube defects.  N Engl J Med . 1999;  341 1509-1519
• 7 Daly L E, Kirke P N, Molloy A M, Weir D G, Scott J M. Folate levels and neural tube defects.  JAMA . 1995;  274 1698-1702
• 8 Wald N J, Law M, Jordan R. Folic acid food fortification to prevent neural tube defects.  Lancet . 1998;  351 834
• 9 Omenn G S, Beresford S AA, Motulsky A G. Preventing coronary heart disease: B vitamins and homocysteine.  Circulation . 1998;  97 421-424
• 10 Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials.  BMJ. 1998;  316 894-898
• 11 Boushey C J, Beresford S AA, Omenn G S, Motulsky A G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease.  JAMA . 1995;  274 1049-1057
• 12 Hankey G J, Eikelboom J W. Homocysteine and vascular disease.  Lancet . 1999;  354 407-413
• 13 Arnesen E, Refsum H, Bonaa K H. Serum total homocysteine and coronary heart disease.  Int J Epidemiol . 1995;  24 704-709
• 14 Wald N J, Watt H C, Law M R. Homocysteine and ischaemic heart disease.  Arch Intern Med . 1998;  158 862-867
• 15 Whincup P H, Mendall M A, Perry I J, Strachan D P. Hyperhomocysteinaemia, Helicobacter pylori and coronary heart disease.  Heart . 1997;  78 524
• 16 Bots M L, Launer L J, Lindemans J. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly.  Arch Intern Med . 1999;  159 38-44
• 17 Stampfer M J, Malinow M R, Willett W C. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians.  JAMA . 1992;  268 877-881
• 18 Folsom A R, Nieto F J, McGovern P G. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins.  Circulation . 1998;  98 204-210
• 19 Alfthan G, Pekkanen J, Juahianen M. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study.  Atherosclerosis . 1994;  106 9-19
• 20 Evans R W, Shaten J, Hempel J D, Cutler J A, Kuller L H. Homocysteine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial.  Arterioscler Thromb Vasc Biol . 1997;  17 1947-1953
• 21 Alfthan G, Aro A, Gey K F. Plasma homocysteine and cardiovascular disease mortality.  Lancet . 1997;  349 97
• 22 Kluijtmans L AJ, Kastelein J JP, Lindemans J. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease.  Circulation . 1997;  96 2573-2577
• 23 Giovannucci E, Stampfer M J, Colditz G A. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study.  Ann Intern Med . 1998;  129 517-524
• 24 Dickinson J. Does folic acid harm people with vitamin deficiency?.  <~>A critical examination of the evidence, relevant to fortification of cereal grain. QJM . 1995;  88 357-364
• 25 Butterworth C E, Tamura T. Folic acid safety and toxicity: a brief review.  Am J Clin Nutr . 1989;  50 353-358